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Introduction
 Statistical data show that skin pathology is quite com-
mon in the world, with an estimated incidence of 250 mil-
lion cases per year. Skin diseases and infections in this seg-
ment can severely affect both the vital prognosis, as, for 
example, in the case of autoimmune pemphigus, and the 
functional prognosis, by affecting the quality of life reported 
in many dermatoses [1, 2]. The idea that “common things 
happen frequently” is a true finding in dermatology – a huge 
chapter, embracing more than 2000 different conditions. It 
is estimated that approximately 70% of a dermatologist’s 
work is caused by only nine types of skin disorders: malig-
nant skin tumours, acne, atopic dermatitis, psoriasis, viral 
warts, infectious skin diseases, benign tumours and vascu-
lar lesions, leg ulcers, contact dermatitis and other eczemas. 
In the United States, almost half of all dermatologist visits 
are for one of these three diagnoses: acne, warts, and skin 
tumours. Whatever the cause, skin diseases should not be 
ignored, as they can worsen and have a negative impact on 
the quality of life [3, 4].
In general, the literature reveals that skin diseases include 
a wide range of causal factors, among which we can notice 
fungal, viral, bacterial, parasitic infections, etc. Likewise, 
quite frequently in the etiopathogenesis of skin diseases 
are involved practically all types of immuno-allergic reac-
tions, which lead to the appearance of allergic dermatoses, 
autoimmune dermatoses or immune-mediated dermatoses. 
Finally yet importantly, skin disorders are caused by other 
extracutaneous pathological diseases, being often attested as 
complications [3].
Most of them, skin diseases are diagnosed by a careful 
examination of the, skin to which is added information re-
lated to the patient›s medical history. Some skin conditions 
are more difficult to diagnose, as they resemble other skin 
diseases, but not only. For example, rosacea requires further 
investigation and clinical examination by a dermatologist, 
so as not to be confused with acne in adolescents [5]. Even 
skin biopsy or tissue culture may be required to accurately 
diagnose and differentiate skin diseases [6].
Among the most serious skin diseases, some authors 
note toxic bullous necrolysis, Stevens-Johnson syndrome, 
pemphigus vulgaris, acne, malignant tumours, skin lym-
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Abstract
Background: Fighting skin diseases is a strict medical, as well as socio-economic issue for the Republic of Moldova, since they may have an aesthetic and 
psychological impact. The author of this scientific article presented an analysis of the pharmaceutical preparations and their forms used in the treatment 
of dermatological diseases based on those recorded in the State Nomenclature of the Republic of Moldova according to Anatomical Therapeutic Chemical 
classification, dose, division, manufacturing country and industrial pharmaceutical company, producer price, and terms of validity.
Material and methods: This research paper is based on the literature and 400 clinical documents, State Nomenclature of the Republic of Moldova, the 
result analysis of dermatological drug manufacturers and producers, the shelf life declared by the manufacturer, etc.
Results: From a total of 10924 preparations registered in the Republic of Moldova on 14.04.2017 – 526 were preparations used in dermatological practice. 
The top of pharmaceutical forms used in dermatological practice and registered in the Republic of Moldova were the ointments – 274 (52.09%) and 
solutions for external use – 162 (30.80%). Of the 27 producing countries, the most pharmaceutical preparations, registered in the Republic of Moldova, 
212 preparations (40.30%) were of domestic origin, which also had the lowest price. The leader was Farmaprim SRL with 46 registered preparations. The 
shelf life of most dermatological preparations – 505 (96%), registered in the Republic of Moldova was at least 24 months – a parameter-guarantor of quality. 
Conclusions: The share of preparations used in dermatological practice in the Republic of Moldova was 4.82%, of which pharmaceutical external forms 
accounted for over 80%. Most preparations registered and used in the dermatological practice in the Republic of Moldova were of local origin, which 
are qualitative, as well as the most accessible.
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phomas, etc., a multitude of diseases and pathological con-
ditions, which involve the use an equally varied arsenal of 
active substances and pharmaceutical forms in their treat-
ment, according to the ATC classification in the D – code 
Dermatological preparations.
The purpose of this study is to assess the pharmaceuti-
cal forms and preparations used in the specific treatment of 
skin diseases based on bibliographic analysis and practice of 
those registered in the State Nomenclature of the Republic 
of Moldova, according to ATC classification, dose, division, 
country and industrial enterprise, shelf life, cost, etc.
Material and methods
The data materials were collected from specialized liter-
ature, clinics (400 documents) and the State Nomenclature 
of the Republic of Moldova, as well as based on the results 
of a systemic analysis of producers and production in this 
segment of drugs, prices for manufactured drugs, the shelf 
life declared by the manufacturer, etc. The methodology of 
scientific research was developed based on the publications 
of local authors [7, 8], using the methods of analytics, de-
scriptive statistics, comparison, price analysis, etc.
Results
In the Republic of Moldova, 526 preparations are used 
in the treatment of dermatological diseases according to the 
ATC classification [9], with code – D Dermatological prepa-
rations, which also includes 11 subcodes, namely:
Table 1
Dermatological preparations registered in the Republic 
of Moldova, according to the ATC classification
Sub-
code
The destination of the 
preparations
Quantity of preparations 
registered in the Republic 
of Moldova
D01 Antifungals for dermatologi-
cal use
98
D02 Emollients and protectors 10
D03 Preparations for the treat-
ment of wounds and ulcers
31
D04 Antipruritic, includes 
antihistamines and local 
anesthesia
7
D05 Antipsoriatic 6
D06 Antibiotics and chemother-
apeutics for dermatological 
usage
66
D07 Corticosteroids, dermato-
logical preparations
93
D08 Antiseptics and disinfec-
tants
160
D09 Medicinal dressings 0
D10 Acne preparations 27
D11 Other dermatological 
preparations
28
Note. These 11 ATC subcodes include another 40 subcodes.
Out of the total number of preparations used in derma-
tological practice, registered in the Republic of Moldova, 
most preparations register subcode D08 Antiseptics and 
disinfectants – 160 preparations, the least belong to sub-
code – D05 Antipsoriatic – 6 preparations (fig. 1). Among 
the sub-codes, most of the registered preparations refer to 
the sub-code D08AX – 68 preparations, D08A – 21 prepa-
rations, etc. No preparation was recorded for the sub-code 
D09 Medicinal dressings [10, 11].
Fig. 1. Preparation used in dermatological practice, registered in 
the Republic of Moldova, according to ATC
On 14.04.2017, 18 pharmaceutical registered prepara-
tions used in dermatological practice were exhibited on the 
pharmaceutical market of the Republic of Moldova, among 
which: ointments – 274 (incl. nasal ointment – 1, ophthal-
mic ointment – 1, creams – 104, vaginal creams – 2, gels 
– 31, liniments – 8, pastes – 3); cutaneous solutions – 162 
(incl. solutions – 7, alcoholic solutions – 5, cutaneous alco-
holic solutions – 8, oropharyngeal solutions – 3, cutaneous 
solutions – 141, oily solutions – 5, shampoos – 10); tablets 
– 16; sprays – 19 (incl. skin spray, sol. – 16, skin spray, susp. 
– 2, buccopharyngeal / cutaneous / vaginal spray, sol. – 1); 
powders – 11 (incl. powder + solvent / skin solution – 1, 
skin powder – 7, powder / cutaneous sol.– 3, powder / in-
jectable sol. – 2), etc. [10, 11].
The distribution of preparations and their pharma-
ceutical forms used in dermatological practice accounts 
for 4.82%, of which ointments – 52.09%, skin solutions – 
30.80%, tablets – 3.04%, spray – 3.61%, powders – 2.09%, 
capsules – 1.52%, herbal products – 0.57%, injectable solu-
tions – 0.38%, suppositories – 0.19% and others (fig. 2).
It is necessary to mention the specific group of herbal 
products used in the treatment of dermatological diseases, 
registered in the Republic of Moldova:
1. Elecasol, herbal combination, vegetable product / tea, 
1.5 g N20, Ukraine;
2. Elecasol, vegetable product / tea, 75g N1, Ukraine;
3. Aerial parts of dentition, Bidens tripartite, fragmented 
plant product, 50g N1, Ukraine.
Fig. 2. The distribution of pharmaceutical forms, used in 
dermatological practice in the Republic of Moldova
18
ORIGINAL  ReseARchA. Znagovan et al. Moldovan Medical Journal. December 2020;63(6):16-20
As it is shown in figure 2 the ointments and skin solu-
tions are among the top pharmaceutical forms used in 
dermatological practice and registered in the Republic of 
Moldova. [11]. 
Dermatological preparations were assessed according 
to the manufacturing country, shown in figure 3. Of the 
27 drug-producing countries, registered in the Republic of 
Moldova regarding preparations and pharmaceutical forms 
used in dermatological practice, the Republic of Moldova 
is on the first place with 212 registered pharmaceutical 
forms (40.30%), followed by the Ukraine – 45 preparations 
(8.55%) and Switzerland – 33 preparations (6.27%). Other 
countries (in alphabetical order): Austria – 12 (2.28%), 
Belgium – 7 (1.33%), Bosnia and Herzegovina – 4 (0.76%), 
Bulgaria – 6 (1.14%), Czech Republic – 3, Croatia – 1, Egypt 
– 1, Estonia – 1, France – 2, Georgia – 1, Germany – 24 
preparations (4.56%), India – 16 (3.04%), Italy – 2, Latvia 
– 3, Great Britain – 20 preparations (3.80%), Netherlands 
– 15, Poland – 14, the Republic of Belarus – 13, Romania 
– 26 preparations (4.94%), Russia – 32 (6.08%), Serbia – 1, 
Slovenia – 6 (1.14%), Turkey – 14, Hungary – 12 prepara-
tions (2.28%) [10, 11]. 
Fig. 3. Top 10 producing countries with the largest number of 
dermatological preparations and their pharmaceutical forms, 
registered in the Republic of Moldova
The list of drug manufacturing companies used in 
dermatological practice and registered in the Republic of 
Moldova, iz as following: Farmaprim SRL, the Republic of 
Moldova ranks first with  46 preparations, followed by Beta 
SRL, Moldova –33 preparations, I.M. RNP Pharmaceuticals 
SRL, Moldova – 24, Universal-Farm SRL, Moldova – 21, 
Bayer Consumer Care AG, Germany – 20, Farmacia Cojusna 
SRL, Moldova – 20, I.M. Farmaco SA, Moldova – 20, Nijfarm 
SA, Russia – 19, Astellas Pharma Europe B.V., Netherlands 
– 15 (fig. 4) [10, 11].
One of the decisive factors in ensuring the competitive-
ness of medicines is their quality. An important parameter 
of the quality of pharmaceutical forms is considered the 
“shelf life”, determined by experimental methods, such as 
the «accelerated aging» method or other methods [12].
As it is shown in figure 5, 237 preparations and their 
pharmaceutical forms were declared by the manufacturers 
as having a 36-month shelf life of (e.g. Triderm® ointment, 
0.5 mg + 10 mg + 1 mg/g, 15 g N1, D07CC01, Betametha-
sonum + Clotrimazolum + Gentamicinum, Schering-Plow 
Central East AG (prod.: Schering-Plough Farma Lda, 
Portugal; Schering-Plow Labo NV, Belgium); 189 prepa-
rations and their pharmaceutical forms were declared to 
have a 24-month shelf life (e.g. skin spray, Mycofin® sol., 
10 mg g, 30 ml N1, D01AE15, Terbinafinum, Nobel Ilac 
Sanayii ve Ticaret A.S. (prod.: Nobel Ilac Sanayii and Ticaret 
AŞ, Turkey); 68 preparations and their pharmaceutical 
forms – 60-month shelf life (e.g. skin spray, Acerbine sol. 
2.15 g + 0.15 g + 0.04 g / 100 g, 80 ml N1, D03AX, Acidum 
malicum + Acidum benzoicum + Acidum salicylicum, 
Pharmazeutische Fabrik Montavit Ges.mbH, Austria); 2 
preparations and their pharmaceutical forms do not have a 
declared shelf life (e.g. Polividon-iodine skin alcohol solu-
tion, 10%, 100ml No1, D08AG02, Povidoni iodidum, Beta 
SRL, the Republic of Moldova) [10, 11]. 
A particularly important index that describes the ac-
cessibility of the population to an adequate and effective 
treatment (and the “cost-effectiveness” index) is the price 
of medicines declared by the manufacturer. Thus, in the 
chapter of “price declared by the manufacturer”, dated on 
14.04.2017, the highest declared prices for preparations and 
their pharmaceutical forms, used in dermatological practice 
Fig. 4. Top 10 dermatological drug manufacturers  
with the highest number of drug preparations,  
registered in the Republic of Moldova
Fig. 5. Shelf life as a parameter of the quality of preparations 
used in dermatological practice, registered in the  
Republic of Moldova
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and registered in the Republic of Moldova (fig. 6) were as 
follows:
1. Gelatin capsules Roaccutane® 20mg, N10x3, D10BA01, 
Isotretinoinum, F. Hoffmann-La Roche Ltd (prod.: 
Catalent Germany Eberbach GmbH, Germany), Swit-
zerland. Shelf life – 36 months, Manufacturer’s price 
(ex works) MDL – 310.38, EUR – 14.06.
2. Skin solution Betadine®, 10%, 1000 ml, N1, D08AG02, 
Povidoni iodidum, Egis Pharmaceuticals PLC, 
Hungary. Shelf life – 36 months, Manufacturer’s price 
(ex works) MDL –258.83, USD – 12.84.
3. Lyophilized / injectable sol., Chymotrypsin 10 mg, 
N10, D03BA, Chymotrypsinum, Samson-Med SRL, 
Russia. Shelf life – 36 months. Manufacturer price (ex 
works) MDL – 222.24, USD – 11.20.
4. Tablets Terbisil®, 250 mg, N14x2, D01BA02, Ter-
binafinum, Gedeon Richter PLC, Hungary. Shelf life 
– 60 months, Manufacturer’s price (ex works) MDL – 
208.58, EUR – 9.50, etc.
Fig. 6. The assessment of the manufacturer's price on 
preparations used in dermatological practice, registered in the 
Republic of Moldova
5. Lyophilized / crystalline sol., Tripsin injection, 10mg, 
N10, D03BA01, Trypsinum, Samson-Med SRL, Russia. 
Shelf life – 36 months, Manufacturer’s price (ex works) 
MDL – 187.21, USD – 9.50.
6. Skin spray, sol., Pilfud®, 50 mg / ml, 60 ml N1, 
D11AX01, Minoxidilum, Bosnalijek, Pharmaceutical 
and Chemical Industry JSC, Bosnia and Herzegovina. 
Shelf life – 36 months, Manufacturer’s price (ex works) 
MDL – 186.41, EUR – 8.35.
7. Tablets Terbonile, 250 mg, N14x2, D01BA02, 
Terbinafinum, Bilim Pharmaceuticals AS, Turkey. 
Shelf life – 60 months, Manufacturer’s price (ex works) 
MDL – 166.86, USD – 8.44.
8. Caps., Roaccutane® 10mg, N10x3, D10BA01, 
Isotretinoinum, F.Hoffmann-La Roche Ltd (prod.: 
Catalent Germany Eberbach GmbH, Germany); 
Switzerland, Shelf life – 36 months, Manufacturer’s 
price (ex works) MDL – 165.02, EUR – 7.76.
9. Skin spray, sol., Pilfud® 2%, 60ml N1, D11AX01, 
Minoxidilum, Bosnalijek, Pharmaceutical and Che-
mical Industry JSC, Bosnia and Herzegovina. Shelf life 
– 36 months. Manufacturer’s price (ex works) MDL – 
164.84, EUR – 7.50.
10. Gel Skinoren® 150 mg / g, 50 g N1, D10AX03, Acidum 
azelaicum, Bayer AG (prod.: Bayer Health Care 
Manufacturing S.R.L., Italy), Germany. Shelf life – 36 
months, Manufacturer’s price (ex works) MDL – 
157.14, EUR – 7.15.
The lowest price was attested at 3% Boric acid-RNP sol., 
10 ml N1, D08AD, Acid boric, RNP Pharmaceuticals SRL, the 
Republic of Moldova. Shelf life – 24 months, Manufacturer’s 
price (ex works) MDL – 3.68, USD – 0.18 [10, 11].
Discussion
1. The fight against skin diseases is a persistent medical 
and socio-economical problem for the Republic of Moldova, 
as these can have a strong psychological and aesthetic im-
pact on people who constantly struggle for improving self-
image. Untreated dermatological skin diseases might leave 
deep marks, which are often difficult to reverse, thus causing 
emotional and physical discomfort among population.
2. According to the ATC classification, out of the total of 
10924 preparations registered in the Republic of Moldova 
on 14.04.2017, 526 are used in dermatological practice. 
The most registered preparations refer to the subcode D08 
Antiseptics and disinfectants – 160 preparations, the least 
ones refer to subcode – D05 Antipsoriasis – 6 preparations. 
Among the subcodes, most of the registered preparations 
belong to the subcode D08AX – 68 preparations, D08A – 21 
et al. The subcode D09 Drug dressings do not contain any 
preparations.
3. According to the data from the State Nomenclature of 
the Republic of Moldova, the distribution of preparations 
used in dermatological practice makes up 4.82%, which 
are present in various pharmaceutical forms: ointments – 
52.09% (274), solutions for external use – 30.80 % (162), 
sprays  – 3.61% (19), tablets – 3.04% (16), powders – 2.09% 
(11), capsules – 1.52% (8), plant products – 0.57% (3), injec-
tions – 0.38% (2), and suppositories – 0.19% (1).
4. Of the 27 dermatological drug manufacturing coun-
tries, most preparations were registered in the Republic of 
Moldova including: the Republic of Moldova – 212 prepa-
rations (40.30%), the Ukraine – 45 preparations (8.55%), 
Switzerland – 33 preparations (6.27%), Russia – 32 (6.08%), 
Romania – 26 preparations (4.94%) etc.
5. The list of dermatological drug manufacturing com-
panies, registered in the Republic of Moldova includs: 
Farmaprim SRL, Republic of Moldova – 46 preparations, 
Beta SRL, Republic of Moldova – 33 preparations, RNP 
Pharmaceuticals SRL, IM, Republic of Moldova – 24, 
Universal-Farm SRL, Republic of Moldova – 21, Bayer 
Consumer Care AG, Germany – 20, etc.
6. The maximum shelf life of 60 months is stated for 68 
pharmaceutical preparations and forms. The shortest shelf 
life – 12 months is stated for 9 pharmaceutical forms.
7. A particularly important index of the accessibility of 
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the population to adequate and effective treatment is the 
price of the medicine declared by the manufacturer. Thus, as 
regarding to the “manufacturer’s price” for the pharmaceu-
tical forms used in dermatological practice, the lowest price 
was registered for 3% Boric acid – RNP, 10 ml N1, D08AD, 
Acidum Boricum, RNP Pharmaceuticals SRL, the Republic 
of Moldova – (ex works) MDL – 3.68, USD – 0.18. Shelf 
life – 24 months. The highest price declared for prepara-
tions in this group is Roaccutane® 20mg, N10x3, D10BA01, 
Isotretinoinum, F. Hoffmann-La Roche Ltd (producer: 
Catalent Germany Eberbach GmbH, Germany), Switzerland. 
Shelf life – 36 months, Manufacturer’s price (ex – works) 
MDL 310.38, EUR – 14.06.
Conclusions
The dermatological drug distribution across the Republic 
of Moldova was 4.82%, of which over 80% accounted for 
pharmaceutical forms for external use. The most regis-
tered and used dermatological drugs from the Republic of 
Moldova were of local origin, which are both qualitative and 
the most accessible ones.
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